Huyabio International has concluded the Phase I drug-drug interaction clinical trial of its drug, HBI-3000, for cardioversion of atrial fibrillation (AF).

A multi-ion channel blocker, HBI-3000 possesses in vitro inhibitory effects on INa-Peak, INa-Late, ICa, L and IKr.

Its preclinical and clinical pharmacology supports the potential for restoring sinus rhythm in AF. 

Furthermore, in preclinical testing, HBI-3000 showed a reduced risk for proarrhythmia. 

The Phase I trial analysed the safety and pharmacokinetics (PK) of HBI-3000 when administered along with paroxetine, a CYP2D6 inhibitor.

Findings showed that no substantial PK interaction was observed between paroxetine and HBI-3000.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Based on the initial safety and pharmacokinetic data from the Phase I trial, the US Food and Drug Administration granted approval for dose escalation in the Phase II HBI-3000-402 clinical trial.

The two-stage, serial cohort dose-escalation and expansion study will assess a single 30-minute intravenous (IV) infusion of HBI-3000 for the conversion of patients with recent-onset AF.

This trial will analyse the pharmacological cardioversion of acute AF. 

Carried out usually using high-energy electrical shock, cardioversion intends to reinstate a normal heart rate and rhythm in AF patients.

Huyabio International president, CEO and executive chair Dr Mireille Gillings said: “I am pleased to announce this positive step in the development of HBI-3000 for potential use in patients suffering from AF, a serious condition that affects more than 30 million people worldwide. 

“The successful completion of this Phase I will enable progression of the ongoing Phase II trial investigating efficacy of HBI-3000 for the conversion of acute AF.”